Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 5
1981 2
1982 4
1983 1
1984 3
1985 6
1986 5
1987 2
1989 3
1990 2
1992 3
1993 3
1994 2
1995 3
1996 4
1997 2
1999 1
2001 1
2002 1
2005 1
2006 1
2007 1
2008 2
2009 2
2011 2
2012 1
2013 3
2014 2
2016 2
2018 1
2019 1
2020 7
2021 7
2022 5
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.
Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, Brooks L, Caldwell JM, Fjällbrant H, Grindebacke H, Ho CN, Keith M, McCrae C, Sinibaldi D, White WI, Datto CJ; MESSINA Trial Investigators. Rothenberg ME, et al. N Engl J Med. 2024 Jun 27;390(24):2252-2263. doi: 10.1056/NEJMoa2313318. N Engl J Med. 2024. PMID: 38924732 Clinical Trial.
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis.
Sordi B, Vanderwert F, Crupi F, Gesullo F, Zanotti R, Bonadonna P, Crosera L, Elena C, Fiorelli N, Ferrari J, Grifoni F, Sciumè M, Parente R, Triggiani M, Palterer B, Mecheri V, Almerigogna F, Santi R, Di Medio L, Brandi ML, Iorno ML, Ciardetti I, Bencini S, Annunziato F, Mannarelli C, Pieri L, Guglielmelli P, Mannelli F, Vannucchi AM. Sordi B, et al. Among authors: almerigogna f. J Allergy Clin Immunol. 2023 Feb;151(2):485-493.e11. doi: 10.1016/j.jaci.2022.09.038. Epub 2022 Oct 27. J Allergy Clin Immunol. 2023. PMID: 36309122
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.
Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, Kalo J, Sponga P, Cesaretti M, Marchetti G, Forniti A, Caroselli C, Ferranti S, Pogliaghi M, Polidori M, Fabiani S, Verdenelli S, Tagliaferri E, Riccardi N, Suardi LR, Carmignani C, Batini S, Puccetti L, Iapoce R, Menichetti F, Falcone M. Tiseo G, et al. Among authors: almerigogna f. Infect Dis Ther. 2023 Jan;12(1):257-271. doi: 10.1007/s40121-022-00729-2. Epub 2022 Nov 28. Infect Dis Ther. 2023. PMID: 36441485 Free PMC article.
Role for CD30 in HIV expression.
Romagnani S, Annunziato F, Manetti R, Almerigogna F, Biagiotti R, Giudizi MG, Ravina A, Giannò V, Tomasévic L, Maggi E. Romagnani S, et al. Among authors: almerigogna f. Immunol Lett. 1996 Jun;51(1-2):83-8. doi: 10.1016/0165-2478(96)02559-x. Immunol Lett. 1996. PMID: 8811349
Schnitzler's syndrome: what's new?
Almerigogna F, Giudizi MG, Cappelli F, Romagnani S. Almerigogna F, et al. J Eur Acad Dermatol Venereol. 2002 May;16(3):214-9. doi: 10.1046/j.1468-3083.2002.00458.x. J Eur Acad Dermatol Venereol. 2002. PMID: 12195558 No abstract available.
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study.
Vivarelli E, Matucci A, Lucenteforte E, Bormioli S, Virgili G, Trotta M, Spinicci M, Bartoloni A, Zammarchi L, Peris A, Pieralli F, Lavorini F, Fontanari P, Morettini A, Nozzoli C, Poggesi L, Rossi O, Annunziato F, Almerigogna F, Vultaggio A. Vivarelli E, et al. Among authors: almerigogna f. Panminerva Med. 2023 Dec;65(4):473-478. doi: 10.23736/S0031-0808.21.04523-7. Epub 2022 Mar 11. Panminerva Med. 2023. PMID: 35274908
Anti-severe acute respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers.
Petito E, Colonna E, Falcinelli E, Mezzasoma AM, Cesari E, Giglio E, Fiordi T, Almerigogna F, Villa A, Gresele P. Petito E, et al. Among authors: almerigogna f. Br J Haematol. 2022 Jul;198(2):257-266. doi: 10.1111/bjh.18245. Epub 2022 May 16. Br J Haematol. 2022. PMID: 35577507
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
Falcone M, Tiseo G, Marchetti G, Kalo J, Galfo V, Occhineri S, Almerigogna F, Matucci T, Riccardi N, Suardi LR, Rina I, Sijoni L, Caparello MC, Cassano Cassano R, Del Giudice ML, Franciosa M, Facella F, Tancredi G, Fazzi R, Galimberti S. Falcone M, et al. Among authors: almerigogna f. Leuk Lymphoma. 2024 Oct;65(10):1474-1481. doi: 10.1080/10428194.2024.2361099. Epub 2024 Jun 4. Leuk Lymphoma. 2024. PMID: 38832710
90 results